| COVID-19 (severe/critical) | Patient characteristics | Smoking [History of smoking vs.Non smoking] | Odds ratio: 1.910 (1.420-2.590) | Patanavanich | | |
| COVID-19 (severe/critical) | Findings | Radiological finding - Chest CT scan [subsegmental areas of consolidation vs.Not applicable] | Odds ratio: 0.202 (0.062-0.659) | Tang | | |
| COVID-19 (severe/critical) | Findings | Radiological finding - Chest CT scan [Bilateral patchy areas of GGO vs.Not applicable] | Odds ratio: 11.628 (2.028-66.667) | Tang | | |
| COVID-19 (severe/critical) | Laboratory Findings | LDH [1 unit increase vs.Not applicable] | Odds ratio: 0.993 (0.986-1.000) | Tang | | |
| COVID-19 (severe/critical) | Laboratory Findings | AST [1 unit increase vs.Not applicable] | Odds ratio: 0.979 (0.957-1.002) | Tang | | |
| COVID-19 (severe/critical) | Laboratory Findings | PT [1 unit increase vs.Not applicable] | Odds ratio: 1.595 (1.165-2.183) | Tang | | |
| COVID-19 (severe/critical) | Symptoms | Myalgia/Arthralgia [Present vs.Not present] | Odds ratio: 0.546 (0.153-1.953) | Tang | | |
| COVID-19 (severe/critical) | Symptoms | Gastrointestinal symptoms [Present vs.Not present] | Odds ratio: 10.000 (0.900-111.111) | Tang | | |
| COVID-19 (severe/critical) | Symptoms | Sputum [Present vs.Not present] | Odds ratio: 0.104 (0.019-0.578) | Tang | | |
| COVID-19 (severe/critical) | Symptoms | Fatigue [Present vs.Not present] | Odds ratio: 8.547 (1.534-47.619) | Tang | | |
| COVID-19 (severe/critical) | Complications | APACHE II score [1 unit increase vs.Not applicable] | Odds ratio: 0.890 (0.738-1.073) | Tang | | |
| COVID-19 (severe/critical) | Complications | Sequential Organ Failure Assessment (SOFA) score [1 unit increase vs.Not applicable] | Odds ratio: 0.442 (0.219-0.890) | Tang | | |
| COVID-19 (severe/critical) | Comorbidities | Cardiovascular disease [Present vs.Not present] | Odds ratio: 1.585 (0.208-12.048) | Tang | | |
| COVID-19 (severe/critical) | Patient characteristics | Age [1 year increase vs.Not applicable] | Odds ratio: 1.101 (1.022-1.186) | Tang | | |
| COVID-19 (death) | Comorbidities | Cardiovascular disease [Present vs.Not present] | Odds ratio: 11.080 (2.590-47.320) | Aggarwal | | |
| COVID-19 (severe/critical) | Comorbidities | Cardiovascular disease [Present vs.Not present] | Odds ratio: 3.140 (2.320-4.240) | Aggarwal | | |
| COVID-19 in children (severe/critical) | Comorbidities | Any comorbidity [Present vs.Not present] | Odds ratio: 3.270 (1.670-6.420) | Götzinger | | |
| COVID-19 in children (severe/critical) | Symptoms | Lower respiratory tract infection [Present vs.Not present] | Odds ratio: 10.460 (5.160-21.230) | Götzinger | | |
| COVID-19 in children (severe/critical) | Patient characteristics | Gender [Male vs.Female] | Odds ratio: 2.120 (1.060-4.210) | Götzinger | | |
| COVID-19 in children (severe/critical) | Patient characteristics | Age [>1 month vs.<=1 month] | Odds ratio: 5.060 (1.720-14.870) | Götzinger | | |
| COVID-19 in children (severe/critical) | Patient characteristics | Age [1 year increase vs.Not applicable] | Odds ratio: 0.900 (0.900-1.000) | Götzinger | | |
| COVID-19 (death) | Laboratory Findings | Creatinine [missing vs.0-1.1] | Hazard ratio: 1.480 (0.560-3.900) | Petrilli | | |
| COVID-19 (death) | Laboratory Findings | Creatinine [>2 vs.0-1.1] | Hazard ratio: 1.490 (1.080-2.040) | Petrilli | | |
| COVID-19 (death) | Laboratory Findings | Creatinine [>1.1-2 vs.0-1.1] | Hazard ratio: 1.360 (1.110-1.680) | Petrilli | | |
| COVID-19 (death) | Laboratory Findings | Lymphocyte count [missing vs.>1.2] | Hazard ratio: 2.160 (1.090-4.270) | Petrilli | | |
| COVID-19 (death) | Laboratory Findings | Lymphocyte count [<0.5 vs.>1.2] | Hazard ratio: 1.380 (1.050-1.810) | Petrilli | | |
| COVID-19 (death) | Laboratory Findings | Lymphocyte count [0.5-0.8 vs.>1.2] | Hazard ratio: 1.040 (0.840-1.280) | Petrilli | | |
| COVID-19 (death) | Laboratory Findings | Lymphocyte count [0.8-1.2 vs.>1.2] | Hazard ratio: 0.890 (0.700-1.140) | Petrilli | | |
| COVID-19 (death) | Vital Signs | Oxygen saturation [missing vs.>92] | Hazard ratio: 1.030 (0.620-1.710) | Petrilli | | |
| COVID-19 (death) | Vital Signs | Oxygen saturation [<88 vs.>92] | Hazard ratio: 2.000 (1.610-2.480) | Petrilli | | |
| COVID-19 (death) | Vital Signs | Oxygen saturation [88-92 vs.>92] | Hazard ratio: 1.460 (1.180-1.790) | Petrilli | | |
| COVID-19 (death) | Symptoms | Body temperature [>39 vs.<38] | Hazard ratio: 1.040 (0.790-1.370) | Petrilli | | |
| COVID-19 (death) | Symptoms | Body temperature [38-39 vs.<38] | Hazard ratio: 1.170 (0.960-1.430) | Petrilli | | |
| COVID-19 (death) | Comorbidities | Cancer [Present vs.Not present] | Hazard ratio: 1.290 (1.030-1.620) | Petrilli | | |
| COVID-19 (death) | Comorbidities | Chronic kidney disease [Present vs.Not present] | Hazard ratio: 0.920 (0.730-1.160) | Petrilli | | |
| COVID-19 (death) | Comorbidities | Asthma or COPD [Present vs.Not present] | Hazard ratio: 1.030 (0.830-1.290) | Petrilli | | |
| COVID-19 (death) | Comorbidities | Diabetes [Present vs.Not present] | Hazard ratio: 1.010 (0.850-1.210) | Petrilli | | |
| COVID-19 (death) | Comorbidities | Hypertension [Present vs.Not present] | Hazard ratio: 0.980 (0.780-1.230) | Petrilli | | |
| COVID-19 (death) | Comorbidities | Hyperlipidaemia [Present vs.Not present] | Hazard ratio: 0.980 (0.820-1.170) | Petrilli | | |
| COVID-19 (death) | Comorbidities | Heart failure [Present vs.Not present] | Hazard ratio: 1.540 (1.230-1.930) | Petrilli | | |
| COVID-19 (death) | Comorbidities | Coronary artery disease [Present vs.Not present] | Hazard ratio: 1.100 (0.900-1.350) | Petrilli | | |
| COVID-19 (severe/fatal) | Findings | Radiological finding during hospitalization [CT-SS>14 vs.Normal] | Hazard ratio: 1.946 (1.095-3.459) | Xu | | |
| COVID-19 (severe/fatal) | Complications | Lymphopenia [Present vs.Not present] | Hazard ratio: 3.014 (1.356-6.697) | Xu | | |
| COVID-19 (severe/fatal) | Complications | Leukocytosis [Present vs.Not present] | Hazard ratio: 6.349 (3.330-12.108) | Xu | | |
| COVID-19 (severe/fatal) | Comorbidities | >=2 comorbidities [Present vs.Not present] | Hazard ratio: 4.778 (2.451-9.315) | Xu | | |
| COVID-19 (death) | Findings | Radiological finding during hospitalization [CT-SS>14 vs.Normal] | Hazard ratio: 2.915 (1.376-6.177) | Xu | | |
| COVID-19 (death) | Complications | Lymphopenia [Present vs.Not present] | Hazard ratio: 4.579 (1.334-15.715) | Xu | | |
| COVID-19 (death) | Complications | Leukocytosis [Present vs.Not present] | Hazard ratio: 9.639 (4.572-20.321) | Xu | | |
| COVID-19 (severe/fatal) | Patient characteristics | Age [>60 years vs.<=60 years] | Hazard ratio: 2.231 (1.124-4.427) | Xu | | |
| COVID-19 (death) | Comorbidities | >=2 comorbidities [Present vs.Not present] | Hazard ratio: 6.734 (3.239-14.003) | Xu | | |